Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.

Yuki MatsubaraToshiki MasuishiTakatsugu OgataTaiko NakazawaKyoko KatoKazuki NozawaYukiya NaritaKazunori HondaHideaki BandoHiroya TaniguchiShigenori KadowakiMasashi AndoMasahiro TajikaKei Muro

Published in: Journal of cancer research and clinical oncology (2022)

Our study suggests omitting fluorouracil from FOLFIRI plus bevacizumab as the second-line chemotherapy decreases adverse events without affecting the treatment efficacy in patients with mCRC who are refractory to fluoropyrimidines. Further randomized prospective studies are warranted to validate our result.

Keyphrases

metastatic colorectal cancer
locally advanced
double blind
open label
placebo controlled
phase iii
randomized controlled trial
squamous cell carcinoma
clinical trial
radiation therapy
combination therapy